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Purpose: Metabolic syndrome (MS) is a clinical condition that shares many com-
mon characteristics with diabetes. However, unlike diabetes, the usefulness of MS 
as a prognostic entity in peripheral arterial disease is uncertain. This study evaluat-
ed the prognostic usefulness of MS in critical lower limb ischemia (CLI) patients. 
Materials and Methods: We compared the 2-year clinical outcomes in 101 con-
secutive CLI patients (66±14 years; 78% men) with 118 affected limbs treated 
with percutaneous transluminal angioplasty (PTA) according to the presence of 
MS and diabetes. Results: The number of MS patients was 53 (52%), of which 45 
(85%) had diabetes. During a 2-year follow-up, the incidence of clinical outcomes, 
including reintervention, major amputation, minor amputation, and survival, was 
not significantly different between MS and non-MS patients; however, the inci-
dence of minor amputation was significantly higher in diabetic than in non-diabet-
ic patients (42% vs. 17%; p=0.011). Cox regression analysis for the 2-year prima-
ry patency demonstrated no association between MS and 2-year primary patency 
[hazard ratio (HR), 1.02; 95% confidence interval (CI), 0.45-2.30; p=0.961], where-
as there was a significant association between diabetes and 2-year primary patency 
(HR, 2.81; 95% CI, 1.02-7.72; p=0.046). Kaplan-Meier analysis revealed no sig-
nificant difference in the 2-year primary patency between MS and non-MS pa-
tients; however, the 2-year primary patency was lower in diabetic than in non-dia-
betic patients (p=0.038). Conclusion: As a prognostic concept, MS might conceal 
the adverse impact of diabetes on the prognosis of CLI patients treated with PTA.
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INTRODUCTION
Metabolic syndrome (MS) is a cluster of several cardiovascular risk factors, with 
insulin resistance as a major characteristic.1,2 Although MS may be a useful clinical 
entity for the prevention of type 2 diabetes and cardiovascular disease (CVD) in 
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ma glucose ≥200 mg/dL, fasting glucose ≥126 mg/dL, a re-
ferral diagnosis of diabetes, or antidiabetic treatment. Kid-
ney function was assessed by the estimated glomerular 
filtration rate (eGFR) calculated with the formula validated 
in the Modification of Diet in Renal Disease study, and end-
stage renal disease was defined as an eGFR of ≤15 mL/
min/1.73 m2 or the need for dialysis.14 The study protocol 
was approved by the local ethics committee of our institu-
tion, and informed consent for the procedure was obtained 
from each patient. Follow-up included clinical examination 
during the hospital stay and at 1 month after PTA to docu-
ment hemodynamic improvement. Subsequent follow-up 
was performed when patients’ clinical status worsened, mea-
sured by using peripheral angiography, computed tomogra-
phy angiogram, or the ankle-brachial index. The causes and 
date of death were examined by chart review, telephone 
contact or checking with the national statistics office.
Procedure of PTA
All patients were medicated with 100 mg of aspirin daily 
before PTA, and then indefinitely in the absence of contra-
indication. Blood samples, including those for complete 
blood count, blood urea nitrogen, and creatinine, were rou-
tinely evaluated 1 day or immediately before and after the 
index procedure. Vascular access for PTA was performed 
by ipsilateral or contralateral puncture of the common fem-
oral artery under local anesthesia. After placement of the 6-7 
Fr sheath, a bolus of 5000 IU heparin was injected through 
the femoral sheath. Additional heparin was administered to 
maintain an activated clotting time between 250 and 300 s, 
if needed. Infrapopliteal lesions were passed with a 0.36-
0.89 mm hydrophilic guidewire. Lesions with failed translu-
minal recanalization or total occlusion were recanalized 
through the subintimal dissection plane with re-entrance 
into the true lumen. PTA was performed with balloons of 
adequate size (2.25-4.0 mm) at 6-10 atm. In case of a flow-
limiting dissection or elastic recoil after balloon dilatation, 
stents were implanted for bailout purposes. Concomitant 
procedures were performed if other proximal lesions were 
present in arteries such as the ipsilateral iliac, femoral, or 
popliteal arteries. 
Definition of technical and clinical outcomes
Technical success was defined as PTA resulting in <30% re-
sidual stenosis with good antegrade flow, and a suboptimal 
result was defined as PTA resulting in 30-50% residual ste-
nosis or sluggish flow. Primary clinical success was defined 
the general population,3,4 the prognostic usefulness of MS 
in established CVD, particularly peripheral arterial disease, 
is uncertain. A recent study has strongly recommended the 
exclusion of condition of established diabetes or CVD from 
the definition of MS;5 however, data justifying this recom-
mendation are scarce.
Peripheral arterial disease with critical lower limb isch-
emia (CLI) is a major atherosclerotic complication that is 
associated with high morbidity and mortality.6 Percutane-
ous transluminal angioplasty (PTA) is a useful therapeutic 
procedure to save limbs from amputation.7 Previous studies 
have reported that diabetes is associated significantly with 
the development and prognosis of CLI.8,9 However, data on 
the prognostic usefulness of MS, which shares many com-
mon characteristics with diabetes,10-12 in patients with CLI 
are scarce. The purpose of this study is to investigate the 
prognostic usefulness of MS compared with diabetes in pa-
tients with CLI who underwent PTA. We compared the 
2-year clinical outcomes of CLI patients treated with PTA 
according to the presence of MS and diabetes, and evaluat-
ed the clinical risk factors for the 2-year primary patency in 
CLI patients after a successful PTA.
MATERIALS AND METHODS
　　　
Subjects and study design
We retrospectively analyzed the clinical data on 118 affect-
ed limbs from 101 consecutive patients with CLI (defined 
by Rutherford-Becker grades 4, 5, or 6),13 who had under-
gone PTA between April 2002 and May 2008. All blood 
samples were obtained after 8 h of fasting and were ana-
lyzed for glucose, triglycerides, high-density lipoprotein 
(HDL) cholesterol, and low-density lipoprotein cholesterol. 
Body mass index (BMI) was calculated as weight (kg)/
height (m2). All patients were divided into 2 groups accord-
ing to the presence of MS or diabetes. MS was defined as the 
presence of 3 or more following: 1) BMI ≥25 kg/m2; 2) HDL 
cholesterol <40 mg/dL in men or <50 mg/dL in women; 3) 
fasting triglycerides ≥150 mg/dL; 4) blood pressure ≥130 
mm Hg systolic or ≥85 mm Hg diastolic, or on treatment; 5) 
impaired fasting glucose, defined as fasting glucose ≥100 
mg/dL, a referral diagnosis of diabetes, or diabetes treat-
ment according to the National Cholesterol Education Pro-
gram-Adult Treatment Panel III definition.1 Diabetes was 
defined as either symptoms of diabetes, including polyuria, 
polydipsia, and unexplained weight loss with a casual plas-
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Baseline characteristics of patients
The baseline characteristics of the 101 CLI patients (66±14 
years; 78% men) in this study are presented in Table 1. This 
study included 53 patients with MS (52%) and 48 patients 
without MS (48%). The incidences of male gender, hyper-
tension, and diabetes were significantly higher in patients 
with MS than in those without MS. Patients with MS had 
significantly higher BMI and triglyceride levels, and had 
significantly lower eGFR and HDL levels than patients 
without MS.
Clinical characteristics of affected limbs
The clinical characteristics of the 118 affected limbs in this 
study are shown in Table 2. The incidence of diabetic limbs 
was significantly higher in the MS group than in the non-MS 
group (86% vs. 54%; p<0.001). There were no significant 
differences between the 2 groups with respect to the lesion 
as improvement in at least 1 clinical category in the Ruther-
ford-Becker classification. Major amputation was defined as 
the loss of limbs below or above the knee, and minor ampu-
tation was defined as a transmetatarsal, or a more distal, am-
putation of the lower extremity. Primary patency was defined 
as persistent patency without any reintervention or amputa-
tion performed on or at the margins of the treated lesions 
after a technically successful PTA.
Statistical analysis
Values are expressed as mean±SD for continuous variables 
and as numbers and percentages, n (%), for categorical 
variables. Continuous variables were compared using Stu-
dent’s t-test, and categorical variables were compared using 
the χ2 test or Fisher’s exact test, as appropriate. Univariate 
Cox regression analysis was performed to identify the indi-
vidual risk factors for the 2-year primary patency. Kaplan-
Meier survival analysis was performed for primary patency 
according to the presence of MS and diabetes, and compar-
isons between groups were performed using the log-rank 
test. SPSS version 18 (SPSS Inc., Chicago, IL, USA) was 
used for all statistical analyses. Values of p<0.05 were con-
Table 1. Baseline Characteristics of the Study Subjects
All (n=101) Non-MS (n=48) MS (n=53) p value
Age (yrs)     66±14     64±18   67±9 0.212
Male sex, n (%) 79 (78) 43 (90) 36 (68) 0.015
Body mass index (kg/m2)   23.2±3.5   22.3±2.4   24.2±4.1 0.009
Smoking, n (%) 41 (41) 23 (48) 18 (34) 0.163
Comorbid disease, n (%)
    Hypertension 69 (69) 21 (44) 48 (91) <0.001
    Diabetes mellitus 70 (70) 25 (52) 45 (85) <0.001
    Cerebrovascular accident  11 (11) 4 (8)   7 (13) 0.531
    Coronary artery disease 54 (54) 23 (48) 31 (59) 0.322
    ESRD 22 (22)   9 (19) 13 (25) 0.630
Laboratory data
    Hemoglobin (g/dL)   11.4±1.9   11.5±1.9   11.3±1.9 0.553
    Sodium (mmol/L)   138±4 138±4 139±4 0.334
    Potassium (mmol/L)     4.4±0.6     4.4±0.5     4.4±0.6 0.999
    Fasting glucose (mg/dL)   151±98   134±81     167±111 0.093
    Total cholesterol (mg/dL)   170±62   165±46   174±73 0.512
    Triglyceride (mg/dL)   141±93   113±85   167±94 0.003
    HDL (mg/dL)     40±15     47±14     34±13 <0.001
    LDL (mg/dL)   101±47     96±36   106±55 0.357
    C-reactive protein (mg/dL)     4.6±8.9     4.6±7.1       4.6±10.2 0.998
    Creatinine (mg/dL)     2.6±2.9     2.4±2.8     2.8±3.0 0.556
    eGFR (mL/min/1.73 m2)     54±33     61±35     47±30 0.029
ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MS, metabolic syn-
drome.
Data are expressed as n (%) or mean±SD. 
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3. The incidences of initial clinical outcomes, including tech-
nical success, primary clinical success, and complications 
after PTA, were not significantly different with respect to 
the presence of MS or diabetes. During the 2-year follow-
up period, the incidences of clinical outcomes, including re-
intervention, major amputation, minor amputation, and sur-
location, incidence of total occlusion, and revascularization 
methods. 
Clinical outcomes with respect to the presence of MS 
and diabetes
The initial and 2-year clinical outcomes are shown in Table 
Table 2. Clinical Characteristics of the Studied Limbs
All (n=118) Non-MS (n=59) MS (n=59) p value
Claudication, n (%) 28 (24) 13 (22) 15 (25) 0.829
Resting pain, n (%) 72 (61) 37 (63) 35 (59) 0.850
Gangrenous change, n(%) 58 (49) 26 (44) 32 (54) 0.357
Clinical category, n (%)
    Rutherford-Becker 4 52 (44) 28 (48) 24 (41) 0.578
    Rutherford-Becker 5 or 6 66 (56) 31 (53) 35 (59) 0.578
Diabetic limb, n (%) 83 (70) 32 (54) 51 (86) <0.001
Left limb, n (%) 63 (53) 33 (56) 30 (51) 0.712
Location, n (%)
    Anterior tibial artery 86 (73) 45 (76) 41 (70) 0.535
    Posterior tibial artery 42 (36) 20 (34) 22 (37) 0.848
    Peroneal artery 30 (25) 15 (25) 15 (25) 0.999
    Dorsalis pedis artery 3 (3) 1 (2) 2 (3) 0.999
Total occlusion, n (%) 60 (51) 34 (58) 26 (44) 0.197
Combined procedure, n (%)
    Iliac artery 7 (6) 5 (9) 2 (3) 0.439
    Femoral artery 42 (36) 24 (41) 18 (31) 0.336
    Popliteal artery 16 (14)   8 (14)   8 (14) 0.999
Antegrade approach, n (%) 58 (49) 27 (46) 31 (53) 0.581
Subintimal approach, n (%) 11 (9)   7 (13) 4 (7) 0.528
Stent implantation, n (%) 10 (9)   8 (14) 2 (4) 0.094
MS, metabolic syndrome.
Data are expressed as n (%) or mean±SD. 













Initial clinical outcomes, n (%)
   Technical success 82 (70) 39 (66) 43 (73) 0.549 27 (77) 55 (66) 0.280
   Suboptimal results 26 (22) 16 (27) 10 (17) 0.267   6 (17) 20 (24) 0.474
   Primary clinical success 98 (83) 50 (85) 48 (81) 0.807 31 (89) 67 (81) 0.422
   Complication
       Dissection 25 (21)   9 (15) 16 (27) 0.176   5 (14) 20 (24) 0.325
       Rupture 6 (5) 1 (2) 5 (9) 0.207 0 (0) 6 (7) 0.177
       Embolism 1 (1) 1 (2) 0 (0) 0.999 1 (3) 0 (0) 0.297
Two-yr clinical outcomes, n (%)
   Reintervention 7 (6) 5 (9) 2 (3) 0.439 2 (6) 5 (6) 0.999
   Major amputation 6 (5) 2 (3) 4 (7) 0.679 2 (6) 4 (5) 0.999
   Minor amputation 41 (35) 20 (34) 21 (36) 0.999   6 (17) 35 (42) 0.011
   Survival* 72 (61) 33 (72) 39 (77) 0.647 24 (83) 48 (71) 0.311
MS, metabolic syndrome.
Data are expressed as n (%) or mean±SD. 
*A total of 101 patients (48 non-MS patients vs. 53 MS patients, 31 non-diabetic patients vs. 70 diabetic patients).
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between patients with MS and those without MS (p=0.961), 
but that patients with diabetes had a lower primary patency 
than those without diabetes (p=0.038) (Fig. 1).
DISCUSSION
To the best of our knowledge, this is the first study to inves-
tigate the usefulness of MS as a prognostic concept com-
pared with diabetes in Korean patients with CLI treated with 
PTA. The results showed that MS had no association with 
clinical outcomes, but that diabetes was significantly asso-
ciated with minor amputation and with the 2-year primary 
patency in patients with CLI treated with PTA. These re-
sults imply that MS may not be an appropriate prognostic 
concept in CLI patients and that the inclusion of diabetes in 
the domain of MS as a component of impaired fasting glu-
cose may not be reasonable.
MS is a common condition affecting approximately 31% 
of adults in Korea.15 Previous studies reported that MS is a 
vival were not different between patients with MS and those 
without MS. However, the incidence of minor amputation 
was significantly higher in patients with diabetes than in 
those without diabetes (42% vs. 17%, p=0.011).
Risk factors related to 2-year primary patency
Univariate Cox regression analysis for identifying individu-
al risk factors related to 2-year primary patency showed a 
significant association between primary patency and the 
Rutherford-Becker grades [hazard ratio (HR), 3.43; 95% 
confidence interval (CI), 1.64-7.19; p=0.001], C-reactive 
protein level (HR, 1.06; 95% CI, 1.01-1.12; p=0.032), or di-
abetes (HR, 2.81; 95% CI, 1.02-7.72; p=0.046), but no sig-
nificant association between primary patency and MS (HR, 
1.41; 95% CI, 0.60-3.30; p=0.478) (Table 4). 
Kaplan-Meier analysis for 2-year primary patency 
according to the presence of MS and diabetes
Kaplan-Meier analysis for 2-year primary patency revealed 
that there was no significant difference in primary patency 
Table 4. Univariate Cox Proportional Hazard Regression for Identifying the Individual Risk Factors of 2-Year Primary Patency
Two-yr primary patency
HR (95% CI) p value
Age ≥65 (yrs) 0.74 (0.33-1.65) 0.458
Male sex 1.95 (0.58-6.56) 0.279
Smoking 0.63 (0.28-1.43) 0.268
LDL 1.00 (0.99-1.01) 0.325
Rutherford-Becker grades 3.43 (1.64-7.19) 0.001
C-reactive protein 1.06 (1.01-1.12) 0.032
Diabetes 2.81 (1.02-7.72) 0.046
MS 1.02 (0.45-2.30) 0.961
ESRD 2.15 (0.91-5.05) 0.080
CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; LDL, low-density lipoprotein; MS, metabolic syndrome.
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Fig. 1. Kaplan-Meier analysis for the 2-year primary patency. Outcomes were analyzed according to the presence of (A) metabolic syndrome (MS) and (B) 
diabetes mellitus (DM).
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could conceal the adverse impact of diabetes in CLI pa-
tients treated with PTA. Furthermore, the exclusion of the 
diabetic condition from the definition of MS might be con-
sidered, as in the previous WHO recommendation. This 
study may provide proper evidence to argue against the in-
clusion of patients with established diabetes in the domain 
of MS and the application of MS in subjects with estab-
lished CVD.
The present study has some limitations. First, we used 
BMI instead of waist circumference to define MS. There-
fore, there may be some degree of MS misclassification. 
However, an earlier study noted that BMI was significantly 
associated with abdominal fat and waist circumference.23 
Second, the criterion of MS may be dependent on race and 
ethnicity.24 However, the present study was performed only 
in Korean patients with CLI. Third, we did not perform an-
giography or any other imaging modality in asymptomatic 
patients after PTA during the follow-up period. Finally, the 
application of the present results to most patients with CVD 
has limited validity because of the small sample size of this 
study. Further prospective studies with larger sample sizes 
are necessary to address these issues.
In conclusion, MS may not be a useful concept for pre-
dicting prognosis in patients with CLI treated with PTA. As 
a prognostic concept, MS may conceal the adverse impact 
of diabetes on the prognosis of CLI patients.
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